|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CFAP20 |
Gene summary for CFAP20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CFAP20 | Gene ID | 29105 |
| Gene name | cilia and flagella associated protein 20 | |
| Gene Alias | BUG22 | |
| Cytomap | 16q21 | |
| Gene Type | protein-coding | GO ID | GO:0001539 | UniProtAcc | Q9Y6A4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29105 | CFAP20 | LZE4T | Human | Esophagus | ESCC | 2.01e-13 | 3.95e-01 | 0.0811 |
| 29105 | CFAP20 | LZE7T | Human | Esophagus | ESCC | 1.51e-10 | 8.84e-01 | 0.0667 |
| 29105 | CFAP20 | LZE8T | Human | Esophagus | ESCC | 9.91e-11 | 2.82e-01 | 0.067 |
| 29105 | CFAP20 | LZE20T | Human | Esophagus | ESCC | 3.77e-04 | 1.44e-01 | 0.0662 |
| 29105 | CFAP20 | LZE24T | Human | Esophagus | ESCC | 4.91e-17 | 5.25e-01 | 0.0596 |
| 29105 | CFAP20 | LZE21T | Human | Esophagus | ESCC | 1.09e-02 | 3.69e-01 | 0.0655 |
| 29105 | CFAP20 | LZE6T | Human | Esophagus | ESCC | 8.11e-09 | 1.43e-01 | 0.0845 |
| 29105 | CFAP20 | P1T-E | Human | Esophagus | ESCC | 7.66e-09 | 5.00e-01 | 0.0875 |
| 29105 | CFAP20 | P2T-E | Human | Esophagus | ESCC | 1.70e-29 | 5.37e-01 | 0.1177 |
| 29105 | CFAP20 | P4T-E | Human | Esophagus | ESCC | 5.79e-26 | 7.91e-01 | 0.1323 |
| 29105 | CFAP20 | P5T-E | Human | Esophagus | ESCC | 5.42e-22 | 5.97e-01 | 0.1327 |
| 29105 | CFAP20 | P8T-E | Human | Esophagus | ESCC | 1.67e-31 | 5.64e-01 | 0.0889 |
| 29105 | CFAP20 | P9T-E | Human | Esophagus | ESCC | 1.88e-14 | 2.81e-01 | 0.1131 |
| 29105 | CFAP20 | P10T-E | Human | Esophagus | ESCC | 1.37e-15 | 3.18e-01 | 0.116 |
| 29105 | CFAP20 | P11T-E | Human | Esophagus | ESCC | 2.34e-14 | 7.94e-01 | 0.1426 |
| 29105 | CFAP20 | P12T-E | Human | Esophagus | ESCC | 6.37e-21 | 4.10e-01 | 0.1122 |
| 29105 | CFAP20 | P15T-E | Human | Esophagus | ESCC | 2.29e-23 | 4.64e-01 | 0.1149 |
| 29105 | CFAP20 | P16T-E | Human | Esophagus | ESCC | 1.38e-23 | 4.11e-01 | 0.1153 |
| 29105 | CFAP20 | P17T-E | Human | Esophagus | ESCC | 4.98e-02 | 1.75e-01 | 0.1278 |
| 29105 | CFAP20 | P19T-E | Human | Esophagus | ESCC | 7.64e-05 | 6.80e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00328864 | Esophagus | ESCC | regulation of microtubule-based process | 134/8552 | 240/18723 | 9.44e-04 | 4.80e-03 | 134 |
| GO:00328863 | Oral cavity | OSCC | regulation of microtubule-based process | 115/7305 | 240/18723 | 2.95e-03 | 1.28e-02 | 115 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CFAP20 | SNV | Missense_Mutation | c.299G>A | p.Arg100His | p.R100H | Q9Y6A4 | protein_coding | tolerated(0.15) | benign(0.052) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298C>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298N>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298C>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| CFAP20 | SNV | Missense_Mutation | c.523N>C | p.Asp175His | p.D175H | Q9Y6A4 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-D5-6932-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CFAP20 | SNV | Missense_Mutation | rs781222045 | c.482G>A | p.Arg161His | p.R161H | Q9Y6A4 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CFAP20 | SNV | Missense_Mutation | novel | c.305N>A | p.Arg102His | p.R102H | Q9Y6A4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CFAP20 | SNV | Missense_Mutation | novel | c.364C>T | p.Pro122Ser | p.P122S | Q9Y6A4 | protein_coding | deleterious(0.01) | possibly_damaging(0.873) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CFAP20 | SNV | Missense_Mutation | novel | c.198N>T | p.Lys66Asn | p.K66N | Q9Y6A4 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| CFAP20 | SNV | Missense_Mutation | rs761689275 | c.338G>A | p.Arg113Gln | p.R113Q | Q9Y6A4 | protein_coding | deleterious(0.04) | possibly_damaging(0.722) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |